[Oncology 2008].

作者信息

Stemmler H-J, Heinemann V

机构信息

Medizinische Klinik und Poliklinik III, Klinikum der LMU München, Standort Grosshadern, Marchioninistrasse 15, 81377 München.

出版信息

Dtsch Med Wochenschr. 2008 Jun;133(25-26):1395-9. doi: 10.1055/s-2008-1081075. Epub 2008 Jun 3.

DOI:10.1055/s-2008-1081075

PMID:18521794

Abstract

摘要

相似文献

[Oncology 2008].

Dtsch Med Wochenschr. 2008 Jun;133(25-26):1395-9. doi: 10.1055/s-2008-1081075. Epub 2008 Jun 3.

[Adverse effects of new oncologic therapies].

Praxis (Bern 1994). 2011 Jul 27;100(15):885-91; quiz 890. doi: 10.1024/1661-8157/a000609.

Challenges and pitfalls of combining targeted agents in phase I studies.

J Clin Oncol. 2008 Aug 1;26(22):3665-7. doi: 10.1200/JCO.2008.17.2676.

[Targeted therapy for metastatic bladder cancer].

Urologe A. 2008 Oct;47(10):1311-4. doi: 10.1007/s00120-008-1747-9.

Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):72-3. doi: 10.5414/cpp50072.

[Targeted therapies and their indications in solid neoplasias].

Rev Med Interne. 2009 May;30(5):416-24. doi: 10.1016/j.revmed.2008.12.022. Epub 2009 Mar 18.

Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?

J Thorac Oncol. 2006 Nov;1(9):927-8.

Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.

Pediatr Blood Cancer. 2012 Nov;59(5):939-40. doi: 10.1002/pbc.24171. Epub 2012 Apr 10.

Molecular therapy of pancreatic cancer.

Minerva Endocrinol. 2010 Mar;35(1):27-33.

Promising systemic therapy for renal cell carcinoma.

Curr Treat Options Oncol. 2005 Sep;6(5):357-65. doi: 10.1007/s11864-005-0039-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Oncology 2008].

Dtsch Med Wochenschr. 2008 Jun;133(25-26):1395-9. doi: 10.1055/s-2008-1081075. Epub 2008 Jun 3.

[Adverse effects of new oncologic therapies].

Praxis (Bern 1994). 2011 Jul 27;100(15):885-91; quiz 890. doi: 10.1024/1661-8157/a000609.

Challenges and pitfalls of combining targeted agents in phase I studies.

J Clin Oncol. 2008 Aug 1;26(22):3665-7. doi: 10.1200/JCO.2008.17.2676.

[Targeted therapy for metastatic bladder cancer].

Urologe A. 2008 Oct;47(10):1311-4. doi: 10.1007/s00120-008-1747-9.

Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.

Int J Clin Pharmacol Ther. 2012 Jan;50(1):72-3. doi: 10.5414/cpp50072.

[Targeted therapies and their indications in solid neoplasias].

Rev Med Interne. 2009 May;30(5):416-24. doi: 10.1016/j.revmed.2008.12.022. Epub 2009 Mar 18.

Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?

J Thorac Oncol. 2006 Nov;1(9):927-8.

Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.

Pediatr Blood Cancer. 2012 Nov;59(5):939-40. doi: 10.1002/pbc.24171. Epub 2012 Apr 10.

Molecular therapy of pancreatic cancer.

Minerva Endocrinol. 2010 Mar;35(1):27-33.

Promising systemic therapy for renal cell carcinoma.

Curr Treat Options Oncol. 2005 Sep;6(5):357-65. doi: 10.1007/s11864-005-0039-5.

[Oncology 2008].

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献